The company has already started first of the facility expansions at various locations in Germany including its Ravensburg Vetter West center for visual inspection and logistics.
Vetter completed structural work for the facility expansion, which will double the plant’s existing capacity. The site is expected to start operations in 2017.
Plans also include the expansion of the Ravensburg Vetter South production site and the Ravensburg Schuetzenstrasse facility.
The site expansions will increase drug product manufacturing capabilities and offer additional logistic services.
Vetter will implement an in-house made enhanced restricted access barrier system (RABS) concept for increased operational excellence in aseptic manufacturing.
All of the planned activities are designed to meet future customer expectations and regulatory requirements at an early stage .
Vetter managing director Peter Soelkner said: "We are continuously monitoring and reacting to a changing marketplace and are pleased that we are in the position to be able to make these strategic investments to further develop our sites and meet these challenges.
"Individually and collectively, they will help us keep pace with the market and allow us to continue to build a successful future for Vetter and our customers."
Earlier this year, Vetter completed the first phase of a multi-functional building at its Ravensburg Schuetzenstrasse site.
The new facility will feature high-tech laboratories and workplaces for Vetter Development Service, as well as a secure data center and further office space for a total area of 8,500m².
Vetter is a contract manufacturer and specializes in production of aseptically prefilled syringe systems, cartridges and vials.
Image: Vetter completed structural work at several of its facilities. Photo: courtesy of Vetter.